Claims

1. Use of a combination therapy comprising a first therapeutic agent and a second therapeutic agent in the manufacture of a medicament for the treatment of cancer in a subject, wherein the first therapeutic agent is a B-cell maturation antigen (BCMA)-specific therapeutic and the second therapeutic agent is an anti-PD-1 antibody, an anti-PD-L1 antibody, an immunomodulating agent or a gamma secretase inhibitor (GSI), and wherein the medicament is to be administered to the subject.

2. The use of claim 1, wherein the BCMA bispecific therapeutic is PF-06863135, the anti-PD-1 antibody is sasanlimab, the immunomodulating agent is lenalidomide or pomalidomide, and/or the GSI is nirogacestat or a pharmaceutically acceptable salt thereof.

3. Use of PF-06863135 in the manufacture of a medicament for the treatment of cancer in a subject, wherein the PF-06863135 is to be administered to the subject according to a dosing regimen of:

(a) 80, 130, 215, 360, 600 or 1000 µg/kg Q1W subcutaneously (SC);

(b) 80, 130, 215, 360, 600 or 1000 µg/kg Q2W SC;

(c) about 16 to 80 mg Q1W SC or Q2W SC;

(d) about 16 to 20, 40 to 44, or 76 to 80 mg Q1W SC;

(e) about 16 to 20, 40 to 44, or 76 to 80 mg Q2W SC;

(f) about 40 mg Q1W SC or Q2W SC;

(g) about 44 mg Q1W SC or Q2W SC;

(h) about 76 mg Q1W SC or Q2W SC;

(i) about 80 mg Q1W SC or Q2W SC;

(j) a priming dosing of about 44 mg Q1W SC for 1 -4 weeks, or a priming dosing of about 32 mg Q1W SC for 1 -4 weeks, followed by a first treatment dosing of about 76 mg Q1W SC or Q2W SC;

(k) a priming dosing of about 40 mg Q1W SC for 1 -4 weeks, followed by a first treatment dosing of about 80 mg Q1W SC or Q2W SC;

(l) a priming dosing of about 44 mg Q1W SC for 1 -4 weeks, or a priming dosing of about 32 mg Q1W SC for 1 -4 weeks, followed by a first treatment dosing of about 76 mg Q1W SC for 2 to 20, 21, 22, 23, 24, 25 to 46, 47 or 48 weeks, followed by a second treatment dosing of about 76 mg Q2W SC;

(m) a priming dosing of about 40 mg Q1W SC for 1 -4 weeks, followed by a first treatment dosing of about 80 mg Q1W SC for 2 to 20, 21, 22, 23, 24, 25 to

46, 47 or 48 weeks, followed by a second treatment dosing of about 80 mg Q2W SC;

(n) a priming dosing of about 44 mg Q1W SC for 1 week, followed by a first treatment dosing of about 76 mg Q1W SC or Q2W SC;

(o) a priming dosing of about 32 mg Q1W SC for 1 week, followed by a first treatment dosing of about 76 mg Q1W SC or Q2W SC;

(p) a priming dosing of about 40 mg Q1W SC for 1 week, followed by a first treatment dosing of about 80 mg Q1W SC or Q2W SC.

(q) a priming dosing of about 44 mg Q1W SC for 1 week, followed by a first treatment dosing of about 76 mg Q1W SC for 2 to 20, 21, 22, 23, 24, 25 to 46, 47 or 48 weeks, followed by a second treatment dosing of about 76 mg Q2W SC;

(r) a priming dosing of about 44 mg Q1W SC for 1 week, followed by a first treatment dosing of about 76 mg Q1W SC for 23 weeks, followed by a second treatment dosing of about 76 mg Q2W SC;

(s) a priming dosing of about 44 mg Q1W SC for 1 week, followed by a first treatment dosing of about 76 mg Q1W SC for 24 weeks, followed by a second treatment dosing of about 76 mg Q2W

(t) a priming dosing of about 32 mg Q1W SC for 1 week, followed by a first treatment dosing of about 76 mg Q1W SC for 2 to 20, 21, 22, 23, 24, 25 to 46, 47 or 48 weeks, followed by a second treatment dosing of about 76 mg Q2W SC;

(u) a priming dosing of about 40 mg Q1W SC for 1 week, followed by a first treatment dosing of about 80 mg Q1W SC for 2 to 20, 21, 22, 23, 24, 25 to 46, 47 or 48 weeks, followed by a second treatment dosing of about 80 mg Q2W SC; or

(v) a priming dosing of about 40 mg Q1W SC for 1 week, followed by a first treatment dosing of about 80 mg Q1W for 23 or 24 weeks, followed by a second treatment dosing of about 80 mg Q2W SC.

4. The use of claim 3, wherein the subject is to be administered PF06863135 in the first treatment dosing of about 76 mg Q1W SC, and after receiving at least 23 weeks of such first treatment dosing, the subject is to be administered PF06863135 in a second treatment dosing of 76 mg Q2W or continue to be administered PF06863135 in the first treatment dosing.

5. Use of PF-06863135 in the manufacture of a medicament for the treatment of cancer in a subject, wherein the PF-06863135 is to be administered to the subject, subcutaneously, a first treatment dosing for 23, 24 or 25 weeks, followed by a second treatment dosing, wherein

(a) the first treatment dosing is about 4 mg Q1W, and the second treatment dosing is about 4 mg Q2W;

(b), the first treatment dosing is about 12 mg Q1W, and the second treatment dosing is about 12 mg Q2W;

(c) the first treatment dosing is about 24 mg Q1W, and the second treatment dosing is about mg 24 mg Q2W;

(d) the first treatment dosing is about 32 mg Q1W, and the second treatment dosing is about 32 mg Q2W;

(e) the first treatment dosing is about 44 mg Q1W, and the second treatment dosing is about 44 mg Q2W; or

(f) the first treatment dosing is about 76 mg Q1W, and the second treatment dosing is about 76 mg Q2W.

6. The use of claim 5, wherein if the dose amount of the first treatment dosing is 32 mg or higher, the use further comprises a priming dosing of PF06863135 to be administered to the subject, and the priming dosing is to be administered for one week, the first dose in the first treatment dosing is to be administered in the week immediately after the week when the priming dosing is to be administered, and wherein

(1) the priming dosing is a single priming dose, and the single priming dose is about 24 mg;

(2) the priming dosing comprises a first priming dose of about 4 mg and a second priming dose of about 20 mg, and the two priming doses are administered on two different days and the first priming dose is to be administered before the second priming dose is to be administered;

(3) the priming dosing comprises a first priming dose of about 8 mg and a second priming dose of about 16 mg, and the two priming doses are to be administered on two different days and the first priming dose is to be administered before the second priming dose is to be administered;

(4) the priming dosing comprises a first priming dose of about 12 mg and a second priming dose of about 12 mg, and the two priming doses are to be administered on two different days and the first priming dose is to be administered before the second priming dose is to be administered;

(5) the priming dosing comprises a first priming dose of about 8 mg and a second priming dose of about 24 mg, and the two priming doses are to be administered on two

different days and the first priming dose is to be administered before the second priming dose is to be administered; or

(6) the priming dosing comprises a first priming dose of about 4 mg and a second priming dose of about 28 mg, and the two priming doses are to be administered on two different days and the first priming dose is to be administered before the second priming dose is to be administered.

7. Use of PF-06863135 in the manufacture of a medicament for the treatment of cancer in a subject, wherein the PF-06863135 is to be administered to a subject

(a) a first treatment dosing of about 32 mg to about 76 mg Q1W SC, starting in week 1; or

(b) a priming dosing during week 1, and a first treatment dosing starting in week 2, wherein the priming dosing is (i) a first priming dose of about 4 mg SC to about 32 mg SC, and a second priming dose of about 12 mg SC to about 44 mg SC, wherein the first priming dose and the second priming dose are to be administered sequentially in week 1, or (ii) a single priming dose of about 24 mg to about 44 mg SC, and wherein the first treatment dosing is about 32 mg to about 76 mg Q1W SC or about 32 mg to about 152 mg Q2W SC , starting in week 2, and wherein the dose amount of the first treatment dosing is higher than the dose amount of each of the respective single priming dose, first priming dose and second priming dose;

wherein week 1, week 2 and any subsequent weeks refer to the first, second and any subsequent weeks when the subject is to be administered PF06863135 respectively, and PF06863135 is to be administered to the subject as a pharmaceutical product comprising PF06863135.

8. The use of claim 7, wherein the subject is to be administered a priming dosing, wherein the priming dosing is a single priming dose of about 24 mg SC, about 32 mg SC or about 44 mg SC in week 1, or priming dosing is (i) a first priming dose of about 12 mg SC and a second priming dose of about 32 mg SC; (ii) a first priming dose of about 4 mg SC and a second priming dose of about 20 mg; (iii) a first priming dose of about 8 mg and a second priming dose of about 16 mg; (iv) a first priming dose of
about 12 mg and a second priming dose of about 12 mg; or (v) a first priming dose of about 8 mg and a second priming dose of about 24 mg.

9. The use of claim 7 or 8, wherein the first treatment dosing is about 32 mg Q1W SC or about 32 mg Q2W SC, about 44 mg Q1W SC, or about 44 mg Q2W SC.

10. The use of claim 9, wherein the subject is to be administered the first treatment dosing until at least the end of cycle 1 or until at least the end of cycle 6, wherein a cycle is 21 days or 28 days, cycle 1 starts on day 1 of week 1, day 1 of week 2, or day 1 of week 3, and cycle 1, cycle 2 and subsequent cycles refer to the first, second and subsequent cycles when the subject is to be administered PF06863135 respectively.

11. The use of claim 10, further comprising PF06863135 to be administered to the subject in a second treatment dosing of about 32 mg to about 152 mg Q2W SC, about 32 mg to about 152 mg Q3W SC, or about 32 mg to about 152 mg Q4W SC, after the subject is no longer on the first treatment dosing, wherein the second treatment dosing is at a dose frequency that is less frequent than the respective first treatment dosing, or the second treatment dosing has a lower dose amount than the first treatment dosing.

12. The use of claim 10, wherein after the first treatment dosing is to be administered to the subject until at least the end of cycle 6, the second treatment dosing of PF06863135 is to be administered to the subject instead of the first treatment dosing, or the subject may continue to be administered the first treatment dosing, and wherein the second treatment dosing is about 32 mg to about 152 mg Q2W SC, about 32 mg to about 152 mg Q3W SC, or about 32 mg to about 152 mg Q4W SC, wherein the second treatment dosing is at a dose frequency that is less frequent than the first treatment dosing, or the second treatment dosing has a lower dose amount than the first treatment dosing.

13. The use of claim 7 or 8, wherein the first treatment dosing is (i) about 76 mg Q1W SC, (ii) about 76 mg Q2W SC, or (iii) about 76 mg Q1W SC for three weeks followed by about 116 mg Q1W SC or (iv) about 76 mg Q1W SC for three weeks followed by about 152 mg Q1W SC.

14. The use of claim 13, wherein the subject is to be administered the first treatment dosing until at least the end of cycle 1, at least the end of cycle 3, or at least the end of cycle 6, wherein a cycle is 21 days or 28 days, and cycle 1 starts on day 1 of week 1, day 1 of week 2, or day 1 of week 3, and cycle 1, cycle 2 and subsequent cycles refer to the first, second and subsequent cycles when the subject is to be administered PF06863135 respectively.

15. The use of claim 14, further comprising PF06863135 to be administered to the subject in a second treatment dosing of about 44 mg to about 152 mg Q2W SC, about 44 mg to about 152 mg Q3W SC, or about 44 mg to about 152 mg Q4W SC, after the

subject is no longer on the first treatment dosing, wherein the second treatment dosing is at a dose frequency that is less frequent than the first treatment dosing, or the second treatment dosing has a lower dose amount than the first treatment dosing.

16. The use of claim 14, wherein after the first treatment dosing is to be administered to the subject until at least the end of cycle 6, a second treatment dosing of about 44 mg to about 152 mg Q2W SC, about 44 mg to about 152 mg Q3W SC, or about 44 mg to about 152 mg Q4W SC is to be administered to the subject instead of the first treatment dosing, or the subject may continue to be administered the first treatment dosing, wherein the second treatment dosing is at a dose frequency that is less frequent than the respective first treatment dosing, or the second treatment dosing has a lower dose amount than that of the first treatment dosing.

17. The use of claim 15 or 16, wherein the first treatment dosing is about 76 mg Q1W SC and the second treatment dosing of about 44 mg Q2W SC, about 76 mg Q2W SC, about 116 mg Q2W SC, about 152 mg Q2W SC, about 44 mg Q3W SC, about 76 mg Q3W SC, about 116 mg Q3W SC, about 152 mg Q3W SC, about 44 mg Q4W SC, about 76 mg Q4W SC, about 116 mg Q4W SC or about 152 mg Q4W SC.

18. The use of any one of claims 15 or 16, wherein the first treatment dosing is about 76 mg Q2W SC, and the second treatment dosing is about 44 mg Q2W SC, about 44 mg Q3W SC, about 76 mg Q3W SC, about 116 mg Q3W SC, about 152 mg Q3W SC, about 44 mg Q4W SC, about 76 mg Q4W SC, about 116 mg Q4W SC or about 152 mg Q4W SC.

19. The use of any one of claims 7 to 18, wherein the subject is to be administered PF06863135 in the first treatment dosing until the end of cycle 1, followed by the second treatment dosing, wherein a cycle is 21 days or 28 days, cycle 1 starts on day 1 of week 1, or day 1 of week 2, or day 1 of week 3, and cycle 1, cycle 2 and subsequent cycles refer to the first, second and subsequent cycles when the subject is to be administered PF06863135 respectively.

20. The use of claim 19, wherein the second treatment dosing is to be administered until at least the end of cycle 6, and thereafter a third treatment dosing of about 76 mg to about 152 mg Q3W SC or about 76 mg to about 152 mg Q4W SC is to be administered to the subject instead of the second treatment dosing, or the subject continues to be administered the second treatment dosing.

21. The use of claim 20, wherein the second treatment dosing is to be administered until the end of cycle 6, the first dose in the third treatment dosing starts in cycle 7 and the third treatment dosing is 116 mg Q4W SC or 152 mg Q4W SC.

22. The use of claim 20 or 21, wherein the first treatment dosing is about 76 mg Q1W SC, the second treatment dosing is about 116 mg Q2W SC and the third treatment dosing is about 116 mg Q4W SC.

23. The use of claim 20 or 21, wherein the first treatment dosing is about 76 mg Q1W SC, the second treatment dosing is about 152 mg Q2W SC and the third treatment dosing is about 152 mg Q4W SC.

24. Use of elranatamab (PF06863135) in the manufacture of a medicament for the treatment of cancer, wherein elranatamab (PF06863135) is to be administered to a subject according a dosing schedule as shown below, and wherein the dosing schedule is described by a week number, a dose amount and a dose frequency corresponding to each week number:

(a)

Week Number	Dose Amount (mg)	Dose Frequency
1	44; 32; 12 plus 32; or A plus B;	Weekly
2 – 24;	32; 44; 76; 116; or 152	Weekly
25 onwards;	32; 44; 76; 116; or 152	Weekly; very two weeks; every three weeks; or every four weeks

, (b)

Week Number	Dose Amount (mg)	Dose Frequency
1	44; 32; 12 plus 32; or A plus B;	Weekly
2 – 25;	32; 44; 76; 116; or 152	Weekly
26 onwards;	32; 44; 76; 116; or 152	Weekly; very two weeks; every three weeks; or every four weeks

, (c)

Week Number	Dose Amount (mg)	Dose Frequency

1	44; 32; 12 plus 32; or A plus B;	Weekly
2 – 26;	44; or 76	Weekly
27 onwards;	44; or 76	Weekly; very two weeks; every three weeks; or every four weeks

,(d)

Week Number	Dose Amount (mg)	Dose Frequency
1	44; 32; 12 plus 32; or A plus B;	Weekly
2 – 24	32; 44; 76; 116; or 152	Every two weeks
25 onwards	32; 44; 76; 116; or 152	Every two weeks; every three weeks; or every four weeks

, (e)

Week Number	Dose Amount (mg)	Dose Frequency
1	44; 32; 12 plus 32; or A plus B;	Weekly
2 – 25	32; 44; 76; 116; or 152	Every two weeks
26 onwards	32; 44; 76; 116; or 152	Every two weeks; every three weeks; or every four weeks

, or (f)

Week Number	Dose Amount (mg)	Dose Frequency
1	44; 32; 12 plus 32; or A plus B;	Weekly
2 – 26	32; 44; 76; 116; or 152	Every two weeks
27 onwards	32; 44; 76; 116; or 152	Every two weeks; every three weeks; or every four weeks

5 wherein when the dose amount is 12 mg plus 32 mg during week 1, the dose amount of 12 mg is to be administered on one day, subsequently, the dose amount of 32 mg is to be administered on another day, wherein A plus B is 4 (A) plus 20 (B), 8 (A) plus 16 (B), 12 (A) plus 12 (B), or 8 (A) plus 24 (B), and wherein when the dose amount is

A mg plus B mg during week 1, the dose amount of A mg is to be administered on one day, subsequently, the dose amount of B mg is to be administered on another day.

25. The use of claim 24, wherein the subject is to be administered elranatamab (PF06863135) according to the dosing schedule as shown below,

(a)

Week Number	Dose Amount (mg)	Dose Frequency
1	44	Weekly
2 – 24	76	Weekly
25 onwards	76	Weekly; every two weeks; every three weeks; or every four weeks

, (b)

Week Number	Dose Amount (mg)	Dose Frequency
1	44	Weekly
2 – 25	76	Weekly
26 onwards	76	Weekly; every two weeks; every three weeks; or every four weeks

, (c)

Week Number	Dose Amount (mg)	Dose Frequency
1	44	Weekly
2 – 26	76	Weekly
27 onwards	76	Weekly; every two weeks; every three weeks; or every four weeks

, (d)

Week Number	Dose Amount (mg)	Dose Frequency
1	44	Weekly
2 – 24	76	Every two weeks
25 onwards	76	Every two weeks; every three weeks; or every four weeks

, (e)

Week Number	Dose Amount (mg)	Dose Frequency

1	44	Weekly
2 – 25	76	Every two weeks
26 onwards	76	Every two weeks; every three weeks; or every four weeks

, or (f)

Week Number	Dose Amount (mg)	Dose Frequency
1	44	Weekly
2 – 26	76	Every two weeks
27 onwards	76	Every two weeks; every three weeks; or every four weeks

.

26. The use of claim 25, wherein the subject is to be administered PF06863135 according to the dosing schedule (a), (b) or (c), and the dose frequency for week 25 onwards, week 26 onwards, and week 27 onwards in the dosing schedule (a), (b), and (c), respectively, is (i) weekly, (ii) every two weeks, or (iii) weekly or every two weeks

27. The use of claim 24, wherein the subject is to be administered elranatamab (PF06863135) according the dosing schedule as shown below,

(a)

Week Number	Dose Amount (mg)	Dose Frequency
1	12 plus 32	Weekly
2 – 24	76	Weekly
25 onwards	76	Weekly; every two weeks; every three weeks; or every four weeks

, (b)

Week Number	Dose Amount (mg)	Dose Frequency
1	12 plus 32	Weekly
2 – 25	76	Weekly
26 onwards	76	Weekly; every two weeks; every three weeks; or every four weeks

, (c)

Week Number	Dose Amount (mg)	Dose Frequency

1	12 plus 32	Weekly
2 – 26	76	Weekly
27 onwards	76	Weekly; every two weeks; every three weeks; or every four weeks

, (d)

Week Number	Dose Amount (mg)	Dose Frequency
1	12 plus 32	Weekly
2 – 24	76	Every two weeks
25 onwards	76	Every two weeks; every three weeks; or every four weeks

, (e)

Week Number	Dose Amount (mg)	Dose Frequency
1	12 plus 32	Weekly
2 – 25	76	Every two weeks
26 onwards	76	Every two weeks; every three weeks; or every four weeks

, or (f)

Week Number	Dose Amount (mg)	Dose Frequency
1	12 plus 32	Weekly
2 – 26	76	Every two weeks
27 onwards	76	Every two weeks; every three weeks; or every four weeks

.

28. The use of claim 27, wherein the subject is to be administered PF06863135 according to the dosing schedule (a), (b) or (c), and the dose frequency for week 25 onwards, week 26 onwards, and week 27 onwards in the dosing schedule (a), (b), and (c), respectively, is (i) weekly, (ii) every two weeks, or (iii) weekly or every two weeks

29. The use of claim 24, wherein the subject is to be administered elranatamab (PF06863135) according the dosing schedule as shown below,

(a)

Week Number	Dose Amount (mg)	Dose Frequency
1	32; or 12 plus 32	Weekly

2 – 24	44	Weekly
25 onwards	44	Weekly; every two weeks; every three weeks; or every four weeks

, (b)

Week Number	Dose Amount (mg)	Dose Frequency
1	32; or 12 plus 32	Weekly
2 – 25	44	Weekly
26 onwards	44	Weekly; every two weeks; every three weeks; or every four weeks

, (c)

Week Number	Dose Amount (mg)	Dose Frequency
1	32; or 12 plus 32	Weekly
2 – 26	44	Weekly
27 onwards	44	Weekly; every two weeks; every three weeks; or every four weeks

, (d)

Week Number	Dose Amount (mg)	Dose Frequency
1	32; or 12 plus 32	Weekly
2 – 24	44	Every two weeks
25 onwards	44	Every two weeks; every three weeks; or every four weeks

, (e)

Week Number	Dose Amount (mg)	Dose Frequency
1	32; or 12 plus 32	Weekly
2 – 25	44	Every two weeks
26 onwards	44	Every two weeks; every three weeks; or every four weeks

, or (f)

Week Number	Dose Amount (mg)	Dose Frequency
1	32; or 12 plus 32	Weekly

2 – 26	44	Every two weeks
27 onwards	44	Every two weeks; every three weeks; or every four weeks

.

30. The use of claim 29, wherein the subject is to be administered PF06863135 according to the dosing schedule (a), (b) or (c), and the dose frequency for week 25 onwards, week 26 onwards, and week 27 onwards in the dosing schedule (a), (b), and (c), respectively, is (i) weekly, (ii) every two weeks, or (iii) weekly or every two weeks.

31. The use of any one of claim 24 to 30, wherein the dose amount and the dose frequency during week 1 are together referred to as a priming dosing, and if the subject is to be administered only one dose of elranatamab in the priming dosing, such one dose is referred to as a single priming dose, if the subject is to be sequentially administered two doses of elranatamab during week 1, the two doses are referred to as a first priming dose and a second priming dose respectively; the dose amount and dose frequency during weeks 2 - 24, weeks 2 – 25 and weeks 2 – 26 in the respective dosing schedules (a) and (d), (b) and (e) and (c) and (f), respectively, are in each dosing schedule together referred to as a first treatment dosing, the dose amount and the dose frequency during week 25 and onwards, week 26 onwards, and week 27 onwards in the respective dosing schedules (a) and (d), (b) and (e) and (c) and (f), are in each dosing schedule together referred to as a second treatment dosing.

32. The use of claim 31, wherein the subject is to be administered PF06863135 of the second treatment dosing for 6 to 18 cycles, thereafter, the subject is to be administered a third treatment dosing of PF06863135 subcutaneously, wherein the third treatment dosing is 32 mg Q2W, 32 mg Q4W, 44 mg Q2W, 44 mg Q4W, 76 mg Q2W, 76 mg Q4W, 116 mg Q2W, 116 mg Q4W, 152 mg Q2W, or 152 mg Q4W, wherein a cycle is 21 days or 28 days, and cycle 1 starts on day 1 week 1, day 1 week 2, or day 1 week 3.

33. The use of claim 32, wherein (i) the first treatment dosing is 32 mg Q1W, the second treatment dosing is 32 mg Q1W or 32 mg Q2W and the third treatment dosing is 32 mg Q2W or 32 mg Q4W, (ii) first treatment dosing is 32 mg Q1W, the second treatment dosing is 32 mg Q2W and the third treatment dosing is 32 mg Q4W, (iii) the first treatment dosing is 44 mg Q1W, the second treatment dosing is 44 mg Q1W or 44 mg Q2W and the third treatment dosing is 44 mg Q2W or 44 mg Q4W; (iv) the first

treatment dosing is 44 mg Q1W, the second treatment dosing is 44 mg Q2W and the third treatment dosing is 44 mg Q4W; (v) first treatment dosing is 76 mg Q1W, the second treatment dosing is 76 mg Q1W or 76 mg Q2W and the third treatment dosing is 76 mg Q2W or 76 mg Q4W, (vi) the first treatment dosing is 76 mg Q1W, the second treatment dosing is 76 mg Q2W and the third treatment dosing is 76 mg Q4W, (vii) the first treatment dosing is 116 mg Q1W, the second treatment dosing is 116 mg Q1W or 116 mg Q2W and the third treatment dosing is 116 mg Q2W or 116 mg Q4W; (viii) the first treatment dosing is 116 mg Q1W, the second treatment dosing is 116 mg Q2W and the third treatment dosing is 116 mg Q4W, (ix) the first treatment dosing is 152 mg Q1W, the second treatment dosing is 152 mg Q1W or 152 mg Q2W and the third treatment dosing is 152 mg Q2W or 152 mg Q4W, or (x) the first treatment dosing is 152 mg Q1W, the second treatment dosing is 152 Q2W and the third treatment dosing is 152 152 mg Q4W.

34. Use of elranatamab (PF06863135) in the manufacture of a medicament for the treatment of cancer, wherein elranatamab (PF06863135) is to be administered to a subject according to a dosing schedule as shown below, and wherein the dosing schedule is described by a week number, a dose amount and a dose frequency corresponding to each week number:

Week Number	Dose Amount (mg)	Dose Frequency
1	44; or 32; or 12 plus 32; or A plus B	Weekly
2 - 4	44 to 152;	Weekly
5 – 24	44 to 152	Weekly; or every two weeks
25 onwards	44 to 152	Every two weeks; every three weeks or every four weeks

wherein when the dose amount is 12 mg plus 32 mg during week 1, the dose amount of 12 mg is to be administered on one day, subsequently, the dose amount of 32 mg is to be administered on another day, wherein A plus B is 4 (A) plus 20 (B), 8 (A) plus 16 (B), 12 (A) plus 12 (B), or 8 (A) plus 24 (B), and wherein the dose amount of A mg is to be administered on one day, subsequently, the dose amount of B mg is to be administered on another day.

35. The use of claim 34, wherein the subject is to be administered elranatamab according the following dosing schedule

Week Number	Dose Amount (mg)	Dose Frequency

1	12 plus 32	Weekly
2 - 4	76	Weekly
5 – 24	116	Every two weeks
25 onwards	116	Every two weeks; every three weeks; or every four weeks

.

36. The use of claim 34, wherein the subject is to be administered elranatamab according the following dosing schedule

Week Number	Dose Amount (mg)	Dose Frequency
1	12 plus 32	Weekly
2 - 4	76	Weekly
5 – 24	152	Every two weeks
25 onwards	152	Every two weeks; every three weeks; or every four weeks

37. The use of any one of claims 34 to 36, wherein the dose amount and the dose frequency during week 1 are together referred to as a priming dosing, and if the subject is to be administered only one dose of elranatamab in the priming dosing, such one dose is referred to as a single priming dose, if the subject is to be sequentially administered two doses of elranatamab during week 1, the two doses are referred to as a first priming dose and a second priming dose respectively, the dose amount and dose frequency during weeks 2 - 4 are together referred to as a first treatment dosing, the dose amount and the dose frequency during weeks 5 - 24 and are together referred to as a second treatment dosing, and the dose amount and dose frequency during week 25 and onwards are together referred to as a third treatment dosing.

38. Use of elranatamab (PF06863135) in the manufacture of a medicament for the treatment of cancer, wherein elranatamab (PF06863135) is to be administered to a subject according to a dosing schedule as shown below, and

wherein the dosing schedule is described by a week number, a dose amount and a dose frequency corresponding to each week number:

Week Number	Dose Amount (mg)	Dose Frequency
1	44; or 32; or 12 plus 32; or A plus B	Weekly
2 - 4	44 to 76	Weekly
5 – 12	44 to 152;	Weekly

13 – 24	44 to 152	Weekly; or every two weeks
25 onwards	44 to 152	Every two weeks; every three weeks; or every four weeks

wherein when the dose amount is 12 mg plus 32 mg during week 1, the dose amount of 12 mg is to be administered on one day, subsequently, the dose amount of 32 mg is to be administered on another day, wherein A plus B is 4 (A) plus 20 (B), 8 (A) plus 16 (B), 12 (A) plus 12 (B), or 8 (A) plus 24 (B), and wherein the dose amount of A mg is to be administered on one day, subsequently, the dose amount of B mg is to be administered on another day.

39. The use of claim 38, wherein the subject is to be administered elranatamab according the following dosing schedule

Week Number	Dose Amount (mg)	Dose Frequency
1	12 plus 32	Weekly
2 to 4	76	Weekly
5 - 12	116	Weekly
13 – 24	116	Weekly; or every two weeks
25 onwards	116	Every two weeks; every three weeks; or every four weeks

40. The use of claim 39, wherein the subject is to be administered elranatamab according the following dosing schedule

Week Number	Dose Amount (mg)	Dose Frequency
1	12 plus 32	Weekly
2 – 4	76	weekly
2 – 12	152	Weekly
13 – 24	152	Weekly or Every two weeks
25 onwards	152	Every two weeks; or every four weeks

41. The use of claim 38, wherein the subject is to be administered elranatamab according the following dosing schedule

Week Number	Dose Amount (mg)	Dose Frequency
1	12 plus 32	Weekly

2 - 4	76	weekly
5 – 12	76	Weekly
13 – 24	76	Weekly; or every two weeks
25 onwards	76	Every two weeks; every three weeks; or every four weeks

42. The use of claim 38, wherein the subject is to be administered elranatamab according the following dosing schedule

Week Number	Dose Amount (mg)	Dose Frequency
1	12 plus 32	Weekly
2 - 4	44	weekly
5 - 12	44	Weekly
13 – 24	44	Weekly or Every two weeks
25 onwards	44	Every two weeks; every three weeks; or every four weeks

43. The use of any one of claims 38 to 42, wherein the dose amount and the dose frequency during week 1 are together referred to as a priming dosing, and if the subject is to be administered only one dose of elranatamab in the priming dosing, such one dose is referred to as a single priming dose, if the subject is to be sequentially administered two doses of elranatamab during week 1, the two doses are referred to as a first priming dose and a second priming dose respectively, the dose amount and dose frequency during weeks 2 – 4 and the dose amount and dose frequency during weeks 5 - 12 are all together referred to as a first treatment dosing, the dose amount and the dose frequency during weeks 13 - 24 and are together referred to as a second treatment

dosing, and the dose amount and dose frequency during week 25 onwards are together referred to as a third treatment dosing.

44. The use of any one of claims 1 to 43 wherein the cancer is multiple myeloma.

45 The use of any one of claims 3 to 44, further comprising sasanlimab to be administered to the subject.

46. The method of any one of claims 3 to 44, further comprising lenalidomide to be administered to the subject.

47. The method of any one of claims 3 to 44, further comprising daratumumab to be administered to the subject.

48. The method of any one of claims 3 to 44, further comprising isatuximab to be administered to the subject.

49. The use of any one of claims 3 to 44, further comprising at least one dose of a premedication to be administered to the subject on the day when the single priming dose, the first priming dose, the second priming dose or the first dose of the first treatment dose of PF06863135 is to be administered to the subject, wherein the premeditation is acetaminophen, diphenhydramine or dexamethasone.

50. The use of any one of claims 3 to 44, further comprising a second therapeutic agent to be administered to the subject.

51. The use of any one of claims 3 to 44, further comprising radiotherapy to be administered to the subject.

52. A combination therapy comprising a first therapeutic agent and a second therapeutic agent for use in therapy, wherein the first therapeutic agent is a B-cell maturation antigen (BCMA)-specific therapeutic and the second therapeutic agent is an anti-PD-1 antibody, an anti-PD-L1 antibody, an immunomodulating agent or a gamma secretase inhibitor (GSI).

53. Elranatamab (PF-06863135) for use in therapy.